All
Phase III Study for Rindopepimut in GBM Discontinued After OS Endpoint was Missed
March 8th 2016The combination of rindopepimut plus temozolomide did not improve overall survival (OS) when compared with temozolomide plus a control in patients with newly diagnosed EGFRvIII-positive glioblastoma multiforme (GBM).
Eribulin Potential Backbone for Breast Cancer Treatment
March 5th 2016Eribulin combination strategies are based on scientific evidence, rather than empirical evidence, and could provide a new chemotherapy-based backbone in the treatment paradigm of the malignancy, according to Christopher Twelves, MD.
FDA Considering Approval Expansion for Blinatumomab in Pediatric ALL
March 4th 2016The FDA has received a supplemental biologics license application to expand the approval of blinatumomab to include pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Ziv-Aflibercept Plus Capecitabine Combo Active, Well-Tolerated in mCRC
March 2nd 2016The combination of ziv-aflibercept and capecitabine demonstrated an acceptable safety profile and encouraging clinical efficacy for patients with metastatic colorectal cancer, according to findings from the ongoing phase II X-TRAP trial.
Everolimus Receives FDA Approval for GI, Lung NETs
February 27th 2016Everolimus (Afinitor) has received FDA approval for adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase III RADIANT-4 trial.
Obinutuzumab Approved by the FDA for Follicular Lymphoma
February 27th 2016Obinutuzumab (Gazyva) plus bendamustine, followed by obinutuzumab alone has been approved by the FDA as a treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.
FDA to Review sNDA for Enzalutamide in Metastatic Prostate Cancer
February 24th 2016The FDA has accepted a supplemental new drug application for a capsulated form of enzalutamide for review in patients with metastatic castration-resistant prostate cancer. This application includes findings from the head-to-head studies, TERRAIN and STRIVE.
Chemoradiation Drastically Improves OS for Elderly Patients With Head and Neck Cancers
February 20th 2016The 5-year overall survival (OS) in elderly patients with locally advanced head and neck cancers was drastically improved with concurrent chemoradiation versus radiation therapy alone, according to an analysis of the National Cancer Data Base.
Smokers Develop Tobacco-Specific Mutations in HPV-Positive Oropharyngeal Squamous Cell Cancer
February 20th 2016Patients with HPV-positive oropharyngeal squamous cell cancer (OPSCC) who smoke can develop tobacco-associated mutations over time. These accumulated mutations result in less dependence on E6/E7 and other HPV-associated mutations.